Caribou Biosciences, Inc.
General ticker "CRBU" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $146.0M (TTM average)
Caribou Biosciences, Inc. follows the US Stock Market performance with the rate: 58.1%.
Estimated limits based on current volatility of 3.3%: low 1.80$, high 1.92$
Factors to consider:
- Total employees count: 147 (-7.0%) as of 2024
- US accounted for 92.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Transition to clinical development, Cybersecurity threats, Pandemic risks, Strategic risks and growth management, Climate change and natural disasters
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.13$, 3.08$]
- 2025-12-31 to 2026-12-31 estimated range: [1.22$, 3.24$]
Financial Metrics affecting the CRBU estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -89.19 <= 0.33
- Positive: Shareholder equity ratio, % of 80.73 > 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 55.89 > -0.66
Short-term CRBU quotes
Long-term CRBU plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $13.85MM | $34.48MM | $9.99MM |
| Operating Expenses | $120.25MM | $150.54MM | $176.61MM |
| Operating Income | $-106.40MM | $-116.06MM | $-166.62MM |
| Non-Operating Income | $7.05MM | $14.18MM | $17.50MM |
| R&D Expense | $82.23MM | $112.08MM | $130.15MM |
| Income(Loss) | $-99.35MM | $-101.88MM | $-149.11MM |
| Taxes | $0.07MM | $0.19MM | $-0.01MM |
| Profit(Loss)* | $-99.42MM | $-102.07MM | $-149.10MM |
| Stockholders Equity | $300.87MM | $368.40MM | $252.95MM |
| Assets | $373.76MM | $432.21MM | $313.31MM |
| Operating Cash Flow | $-90.97MM | $-93.29MM | $-138.20MM |
| Capital expenditure | $6.45MM | $11.61MM | $6.50MM |
| Investing Cash Flow | $-93.25MM | $-68.18MM | $86.61MM |
| Financing Cash Flow | $2.13MM | $154.30MM | $16.72MM |
| Earnings Per Share** | $-1.64 | $-1.38 | $-1.65 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.